Enlicitide decanoate - Merck Sharp & Dohme
Alternative Names: Enlicitide Chloride; MK-0616Latest Information Update: 08 Sep 2025
At a glance
- Originator Merck Sharp & Dohme Corp.
- Class Antihyperlipidaemics; Cyclic peptides; Urologics
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
Most Recent Events
- 02 Sep 2025 Topline efficacy and adverse events data from the phase III CORALreef Lipids trial in Hypercholesterolaemia released by Merck Sharp & Dohme Corp.
- 02 Sep 2025 Merck Sharp & Dohme completes enrolment in the phase III CORALreef Outcomes trial in Hypercholesterolaemia (Treatment-experienced) in USA, Argentina, Australia, Taiwan, Brazil, Canada, China, Chile, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Turkey, and United Kingdom (PO), prior to September 2025 (NCT06008756)
- 21 Aug 2025 Phase-II/III clinical trials in Hyperlipoproteinaemia type IIa (In children, In adolescents, Treatment-experienced) in USA (PO) (NCT07058077)